Services

Histology

Pharmacology

Medical Device Testing

In Vitro Screening

Animal Model Development

Custom Assay Development

Vivarium Rental

Toxicology

Species

Non-human Primates

Dogs

Mini-pigs / Pigs

Rabbits

Mice

Rats

Sheep

Guinea Pigs

Hamsters

Other Species

Therapeutic Areas

Oncology

Immunology & Inflammation

Neurology / CNS

Cardiovascular

Dermatology & Wound Healing

Metabolism

Gastroenterology

Hepatology

Pulmonology

Infectious Diseases & Sepsis

Musculoskeletal

Nephrology & Urology

Capabilities

GLP / IND-Enabling Studies

Small and Large Animal Housing

Bioanalytical Platforms

About

News

Contact

Career

Request a Quote

Logo
☰
  • Services ⌄
    • Histology
    • Pharmacology
    • Medical Device Testing
    • In Vitro Screening
    • Animal Model Development
    • Custom Assay Development
    • Vivarium Rental
    • Toxicology
  • Species ⌄
    • Non-human Primates
    • Dogs
    • Mini-pigs / Pigs
    • Rabbits
    • Mice
    • Rats
    • Sheep
    • Guinea Pigs
    • Hamsters
    • Other Species
  • Therapeutic Areas ⌄
    • Oncology
    • Immunology & Inflammation
    • Neurology / CNS
    • Cardiovascular
    • Dermatology & Wound Healing
    • Metabolism
    • Gastroenterology
    • Hepatology
    • Pulmonology
    • Infectious Diseases & Sepsis
    • Musculoskeletal
    • Nephrology & Urology
  • Capabilities ⌄
    • GLP / IND-Enabling Studies
    • Small and Large Animal Housing
    • Bioanalytical Platforms
  • About ⌄
    • News
  • Contact ⌄
    • Career
    • Request a Quote

Hackers Make Off With Novartis Data, but Company Denies Major Breach

  • Post author:PacConAdmin
  • Post published:June 6, 2022
  • Post category:Drug Industry Daily

Novartis confirmed Monday it was the victim of a cyberattack that ended in stolen data but maintained the hackers didn’t get away with any sensitive information. Source: Drug Industry Daily

Continue ReadingHackers Make Off With Novartis Data, but Company Denies Major Breach

GSK’s Jemperli Eliminates Rectal Tumors in Study

  • Post author:PacConAdmin
  • Post published:June 6, 2022
  • Post category:Drug Industry Daily

In a stunning mid-study analysis of 12 patients, GlaxoSmithKline’s anti-PD-1 antibody Jemperli (dostarlimab) completely eradicated locally advanced rectal tumors in every patient, sparing them life-altering surgery and causing minimal side…

Continue ReadingGSK’s Jemperli Eliminates Rectal Tumors in Study

OTC Drugmaker in Mexico Gets Warning Letter for Improper Listing

  • Post author:PacConAdmin
  • Post published:June 6, 2022
  • Post category:Drug Industry Daily

The FDA issued a warning letter to Grimann, an over-the-counter (OTC) drug manufacturer located near Mexico City, for failure to comply with drug registration and listing requirements. Source: Drug Industry…

Continue ReadingOTC Drugmaker in Mexico Gets Warning Letter for Improper Listing

ASCO Highlights Breast Cancer Treatments by AstraZeneca, Gilead

  • Post author:PacConAdmin
  • Post published:June 6, 2022
  • Post category:Drug Industry Daily

Breast cancer treatments by AstraZeneca (AZ)/Daiichi Sankyo and Gilead are grabbing headlines at the annual meeting of the American Society of Clinical Oncology this week. Source: Drug Industry Daily

Continue ReadingASCO Highlights Breast Cancer Treatments by AstraZeneca, Gilead

J&J’s, AbbVie’s Imbruvica Significantly Curtails Rare Lymphoma Progression

  • Post author:PacConAdmin
  • Post published:June 5, 2022
  • Post category:Drug Industry Daily

Johnson & Johnson’s (J&J) and AbbVie’s blockbuster cancer drug Imbruvica (ibrutinib) plus chemotherapy significantly slashed cancer spread in older patients suffering from mantle cell lymphoma (MCL) in a phase 3…

Continue ReadingJ&J’s, AbbVie’s Imbruvica Significantly Curtails Rare Lymphoma Progression

BMS to Buy Oncology-Focused Turning Point for $4.1B, Netting Three Breakthrough Therapy Candidates

  • Post author:PacConAdmin
  • Post published:June 5, 2022
  • Post category:Drug Industry Daily

Bristol Myers Squibb (BMS) is buying clinical-stage oncology-focused Turning Point Therapeutics for $4.1B, the companies announced Friday. Source: Drug Industry Daily

Continue ReadingBMS to Buy Oncology-Focused Turning Point for $4.1B, Netting Three Breakthrough Therapy Candidates

FDA Committee to Review Novavax’s EUA Application for Its COVID-19 Vaccine

  • Post author:PacConAdmin
  • Post published:June 5, 2022
  • Post category:Drug Industry Daily

Novavax goes before FDA’s Vaccines and Related Biologics Advisory Committee this week, seeking Emergency Use Authorization of its COVID-19 vaccine. Source: Drug Industry Daily

Continue ReadingFDA Committee to Review Novavax’s EUA Application for Its COVID-19 Vaccine

Immune Modulators Used in Rheumatoid Arthritis Also Cut COVID-19 Mortality

  • Post author:PacConAdmin
  • Post published:June 5, 2022
  • Post category:Drug Industry Daily

Bristol Myers Squibb’s Orencia (abatacept) and Janssen’s Remicade (infliximab) reduced the risk of death among patients hospitalized with COVID-19 by around 40 percent, according to a study commissioned by the National…

Continue ReadingImmune Modulators Used in Rheumatoid Arthritis Also Cut COVID-19 Mortality

Pfizer, BioNTech Contest Alnylam’s Patent Claims Over COVID-19 Vaccine Technology

  • Post author:PacConAdmin
  • Post published:June 2, 2022
  • Post category:Drug Industry Daily

Pfizer and BioNTech hit back against Alnylam Pharmaceuticals’ claims alleging their COVID-19 vaccine infringed on Alnylam’s patent for lipid-nanoparticle delivery (LNP) technology. Source: Drug Industry Daily

Continue ReadingPfizer, BioNTech Contest Alnylam’s Patent Claims Over COVID-19 Vaccine Technology

Nephron Voluntarily Recalls 2M Doses After FDA Inspection Finds Lack of Sterility

  • Post author:PacConAdmin
  • Post published:June 2, 2022
  • Post category:Drug Industry Daily

Nephron Pharmaceuticals of South Carolina has issued a voluntary recall of about 2 million doses of its medicines after an FDA inspection found a “lack of assurance of sterility” across…

Continue ReadingNephron Voluntarily Recalls 2M Doses After FDA Inspection Finds Lack of Sterility
  • Go to the previous page
  • 1
  • …
  • 105
  • 106
  • 107
  • 108
  • 109
  • 110
  • 111
  • …
  • 385
  • Go to the next page

Stay Connected

Keep up with the latest news & insights.

Contact Us

Phone:
+1 858-605-5882
Fax:
+1 858-605-5916
Email:
info@biolegacyresearch.com
Mail:

6042 Cornerstone Court W

Suite E

San Diego, CA 92121

Social:
© 2025 BioLegacy Research. All rights reserved.